menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

In the Pipeline: New and Emerging Therapies for Dry Macular Degeneration

Dr. Scott Cousins discusses the natural history of age-related macular degeneration (AMD) & the paradigms contributing to geographic atrophy.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    CME Information 

    Faculty
    Scott W. Cousins, MD
    Robert Machemer Professor of Ophthalmology and Immunology
    Vice Chair for Research, Department of Ophthalmology
    Duke University School of Medicine
    Durham, NC

    Host
    Adrienne W. Scott, MD
    Assistant Professor of Ophthalmology
    Wilmer Eye Institute
    Johns Hopkins University School of Medicine
    Baltimore, MD

    Activity Planners
    Stephanie Stowell Wenick, MPhil
    Manager, Educational Strategy and Content
    Med-IQ
    Baltimore, MD

    Amy Sison
    Director of Continuing Medical Education
    Med-IQ
    Baltimore, MD

    Activity Overview
    This podcast discusses the natural history of age-related macular degeneration (AMD) and examines the paradigms currently contributing to the development of geographic atrophy. Potential therapies for the management of geographic atrophy, including complement inhibitors, anti-amyloid agents, visual cycle therapeutics, and cell therapy techniques, are also explored. 

    Learning Objectives
    Upon completion, participants should be able to:

    • Understand the epidemiology and vision-related impact of macular degeneration
    • Explore new therapies for late-stage geographic atrophy

    Target Audience
    This activity is intended for ophthalmologists.

    Statement of Need
    Age-related macular degeneration (AMD) is the leading cause of irreversible blindness. One-half of all cases of advanced AMD are the result of geographic atrophy, also known as dry AMD. Currently, no treatments are approved for geographic atrophy. However, recent advances in the understanding of the pathobiology of AMD have led to the emergence of several therapeutic agents that are in clinical development. Ophthalmologists must be made aware of these advances so that they may prevent future vision loss in their patients with dry AMD. 

    Providership Statement
    Co-provided by Med-IQ® and Duke University Health System Department of Clinical Education and Professional Development.

          

    Accreditation/Designation Statements
    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions to Receive Credit
    To receive credit, read the introductory CME material, listen to the podcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

    Original Release Date: December 9, 2016
    Expiration Date: December 8, 2017
    Estimated Time to Complete This Activity: 15 minutes

    The evaluation, attestation, and post-test may be accessed by clicking the “Take Post-Test” tab above.

    Disclosure Policy
    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    Disclosure Statement
    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

    Scott W. Cousins, MD, has indicated no real or apparent conflicts.

    Adrienne W. Scott, MD
    Consulting fees/advisory boards: Allergan, Inc.
    Contracted Research: ThromboGenics NV

    The peer reviewers and other activity planners have no financial relationships to disclose.

    Statement of Evidence-Based Content
    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

    Contact Information
    For CME-related questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

    Hardware/Software Requirements
    ReachMD requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8/IE9/IE10 are advised to update their browsers for the best experience.

    Browser
    Microsoft Internet Explorer 11.0 or later
    Mozilla Firefox - latest version
    Download: http://www.mozilla.org/en-US/firefox/new/ 
    Google Chrome - latest version
    Download: http://www.google.com/chrome 
    Apple Safari - latest version
    Download: http://www.apple.com/safari/download/ 

    PDF Viewer
    Adobe Acrobat Reader® or Adobe Reader
    Download: https://get.adobe.com/flashplayer/

    Adobe Flash Player
    Adobe Flash Player 9 or later
    Download: http://get.adobe.com/flashplayer/ 

    For technical support, go to https://reachmd.com/pages/about/.

    ADA Statement
    Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

    Disclaimer
    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

    Privacy Policy 
    https://reachmd.com/pages/privacy/

    Copyright
    © 2016 Duke University Health System and Med-IQ®. All rights reserved.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.